Evidence map›Paper›PMID 35292040›Full record

ArticleHarm reduction journal2022

Changes in cannabis use and associated correlates during France's first COVID-19 lockdown in daily cannabis users: results from a large community-based online survey.

Salim Mezaache, Cécile Donadille, Victor Martin, Maëla Le Brun Gadelius, Laurent Appel, Bruno Spire, Laelia Briand Madrid, Martin Bastien, Perrine Roux

Abstract read
In one paragraph

Article in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Evolution of psychiatry- and addiction-related visits in an emergency department before and during the first COVID-19 lockdown: a retrospective study.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Salim MezaacheSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Cécile DonadilleSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Victor MartinAssociation Bus 31/32, Marseille, France.
Maëla Le Brun GadeliusAssociation Bus 31/32, Marseille, France.
Laurent AppelAssociation Bus 31/32, Marseille, France.
Bruno SpireSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Laelia Briand MadridSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Martin BastienSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.
Perrine RouxSciences économiques & sociales de la santé & traitement de l'information médicale, Aix-Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France. perrine.roux@inserm.fr.ORCID 0000-0002-5069-4982

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLockdown measures during the first wave of the COVID-19 pandemic in France led to serious public health concerns over people who use illicit drugs, especially in terms of mental health. We assessed changes in cannabis use during the first lockdown in France among daily cannabis users and associated correlates.

methodsCANNAVID is a French, national, cross-sectional web-based survey, conducted from 17 April to 11 May 2020. Daily cannabis users aged ≥ 18 years and living in France were invited to participate through advertisements. Respondents completed an ad hoc questionnaire on a dedicated online platform. We analyzed changes in cannabis use during the first lockdown (i.e., stopped, decreased, unchanged, or increased) and performed a multinomial logistic regression analysis to evaluate correlates of these changes.

resultsOf the 4019 participants, 74.0% were men. Median age was 27 years (interquartile range: 22-37). With regard to cannabis use, 293 (7.3%) persons stopped, 1153 (28.7%) decreased, 1146 (28.5%) did not change, and 1427 (35.5%) increased their use during the lockdown. A multinomial logistic regression model revealed several sociodemographic, behavioral and health-related factors associated with changes in cannabis use. Compared with participants with an unchanged level of cannabis use during the lockdown, those who increased and those who stopped cannabis use were more likely to have increased tobacco and alcohol use and to have experienced depression and sleep disorders intensification. Those who stopped cannabis use were also more likely to have increased benzodiazepine use and to have experienced pain increase during lockdown.

conclusionsFrance's first COVID-19-related lockdown had a differential impact on daily cannabis users' consumption patterns. Most study respondents reported changes to their cannabis consumption pattern. Those who reported a stable cannabis use were more likely to report fewer negative changes. Specific interventions are needed for this population, as well as research to assess the long-term impacts of these changes.

Indexed as

CannabisCOVID-19AdolescentAdultCommunicable Disease ControlCross-Sectional StudiesHumansMalePandemicsPrevalenceSurveys and QuestionnairesCannabisCOVID-19Mental healthPainQuarantineSleep disorders

Identifiers

PMID35292040
PMCPMC8922077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.